R. Ferris
Oncology · 2011–2022
A researcher in the Science corpus: 11 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 78 citations into it
- Immunology — 31 citations into it
Whom R. Ferris trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from R. Ferris's perspective
Ordered by how strongly the researchers R. Ferris trusts endorse each paper. Same corpus, a different order for every researcher.
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
- Cancer immunoediting: from immunosurveillance to tumor escape (Nature Immunology)
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody (Clinical Cancer Research)
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma (New England Journal of Medicine)
- Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. (Clinical Cancer Research)
- Molecular pathogenesis and mechanisms of thyroid cancer (Nature Reviews. Cancer)
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers (Genome Biology)
- New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape (Current Opinion in Immunology)
Their papers
- Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. (2011) — 703 citations
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014) — 2,692 citations
- Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment (2022)
- B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma (2021)
- The changing therapeutic landscape of head and neck cancer (2019) — 637 citations
- Immune landscape of viral- and carcinogen-driven head and neck cancer (2019)
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) (2019) — 606 citations
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression (2018) — 691 citations
- KRAS-variant is a biomarker of cetuximab response potentially through altered immunity in head and neck cancer: Re-analysis of NRG Oncology/RTOG 0522 (2017)
- Comprehensive genomic characterization of head and neck squamous cell carcinomas (2015) — 3,702 citations
- Immunology and Immunotherapy of Head and Neck Cancer. (2015) — 602 citations